Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/162720
Title: Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study
Author: Corominas, Héctor
Alegre, Cayetano
Narváez García, Francisco Javier
Fernández-Cid, Carlos Marras
Torrente Segarra, Vicenç
Gómez Rodríguez, Manuel
Maceiras Pan, Francisco
Morlà, Rosa María
Martínez Rodríguez, Fernando José
Gómez-Centeno, Antoni
Losada Ares, Laura
Gonzalez Molina, Rocío
Paredes González-Albo, Silvia
Dalmau-Carolà, Joan
Pérez-García, Carolina
Barbazán Álvarez, Ceferino
Ercole, Liliana
Terrancle, Maria Ángeles
ACT-AXIS Study Group.
Keywords: Fatiga
Artritis reumatoide
Farmacologia
Fatigue
Rheumatoid arthritis
Pharmacology
Issue Date: 29-Jun-2019
Publisher: Lippincott, Williams & Wilkins. Wolters Kluwer Health
Abstract: To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 ± 12.5 years, disease duration 8.7 ± 7.4 years). Mean change in C-reactive protein level from baseline to week 12 was -11.2 ± 4.0 (P < .001). Mean Disease Activity Index score (DAS28) decreased from 5.5 ± 1.0 at baseline to 2.7 ± 1.3 (P < .001) at week 24. Mean change in Functional Assessment of Chronic Illness Therapy score was -5.4 ± 11.2 points at week 24. Multiple regression analysis showed that the improvement in DAS28, sleep, and depression explained 56% and 47% of fatigue variance at week 12 and 24, respectively.Tocilizumab is effective in reducing disease activity and results in a clinically significant improvement in fatigue, pain, swollen joint count, morning stiffness, sleepiness, depression, and DAS28; the last 3 were specifically identified as factors explaining fatigue variance with the use of TCZ in RA patients.
Note: Reproducció del document publicat a: https://doi.org/10.1097/MD.0000000000015947
It is part of: Medicine, 2019, vol. 98, num. 26, p. 15947
URI: http://hdl.handle.net/2445/162720
Related resource: https://doi.org/10.1097/MD.0000000000015947
ISSN: 0025-7974
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
692535.pdf394.2 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons